Sign in

CIK 0001789972

  • Non-accelerated filer
  • Smaller reporting company

Cullinan Therapeutics, Inc.

Sign in to watch
Ticker
CGEM
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
813879991
Phone
+1 617-410-4650
Business address
ONE MAIN STREET, SUITE 1350, CAMBRIDGE, MA, 02142
Former names
Cullinan Oncology, Inc., Cullinan Management, Inc., Cullinan Oncology, LLC
  1. 4 Open-market buy 10% owner bought 165,667 shares at $8.40 ($1,391,686)
  2. 4 Open-market buy 10% owner bought 248,749 shares at an average $8.46 ($2,103,912)
  3. 4 Open-market buy 10% owner bought 1,459,641 shares at an average $6.73 ($9,826,941)
  4. 3 Insider Initial Statement of Ownership
  5. 4 Derivatives Options or other derivatives
  6. 4 Derivatives Options or other derivatives
  7. 3 Insider Initial Statement of Ownership
  8. 3 Insider Initial Statement of Ownership
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Derivatives Options or other derivatives
  12. 4 Derivatives Options or other derivatives
  13. 4 Derivatives Options or other derivatives
  14. 4 Open-market sale Chief Medical Officer sold 4,895 shares at $8.53 ($41,754)
  15. 4 Open-market sale President and CEO sold 12,529 shares at $8.53 ($106,872)
  16. 4 Open-market sale Chief Scientific Officer sold 3,756 shares at $8.53 ($32,039)
  17. 4 Open-market sale Chief Legal Officer sold 3,756 shares at $8.53 ($32,039)
  18. 4 Grant or award Chief Scientific Officer acquired 50,000 shares (grant or award)
  19. 4 Grant or award Chief Business Officer acquired 37,500 shares (grant or award)
  20. 4 Grant or award Chief Legal Officer acquired 50,000 shares (grant or award)

Page 3 of 13 · 253 filings